Treatment of hospitalized patients with COVID-19
Summary
In collaboration with multiple other Canadian centers as well as the World Health Organization SOLIDARITY protocol, this study will investigate the effectiveness of anti-viral and anti-inflammatory agents against COVID-19 in patients who are admitted to hospital with this condition.
The drugs being tested at this time are Artesunate, Imatinib, Infliximab, Losartan, LSALT and Dexamethasone. Other treatments may be added as promising agents are identified while those found ineffective will be removed.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 18 to 99
Inclusion criteria:
Adult patients with confirmed COVID-19 on a nose or throat swab, and admitted to a participating hospital, will be considered for trial eligibility.
Exclusion criteria:
The following individuals are not eligible for this study:
-Outpatients with COVID-19
-Unconfirmed patients suspected of having COVID-19 (no swab taken, or no results received as yet).
-Patients who are allergic to the study drugs or have other medical issues which increases the risk of the study drugs.
Participate
Additional information
Contact information
Only inpatients will be considered with the treating physician contacting the study team.
Principal investigator:
Alain Tremblay
Clinical trial:
Yes
REB-ID:
REB20-0495